Open a free Demat account & get ₹500 in stocks.Claim
Nifty 5025,800.62.27%H 25,808.8 · L 25,345.2as of 20 Nov, 3:31 PM IST|Sensex83,919.712.3%H 84,037.96 · L 82,403.27as of 20 Nov, 3:32 PM IST|Bank Nifty64,635.24.19%H 64,680.8 · L 62,598.55as of 20 Nov, 3:31 PM IST|USD / INR₹92.660.66%H ₹93.29 · L ₹92.64as of 4:06 AM IST|Gold Intl (10g)₹1,05,429.853.98%H ₹1,08,382.13 · L ₹1,04,363.34as of 3:29 AM IST|Silver Intl (1kg)₹1,22,380.857.39%H ₹1,28,636.93 · L ₹1,20,995.58as of 3:29 AM IST|Crude WTI₹7,748.231.43%H ₹7,789.93 · L ₹7,485.07as of 3:29 AM IST|Bitcoin₹54,62,2015.63%H ₹56,15,877.06 · L ₹53,08,524.94as of 6:06 AM IST|Ethereum₹1,50,3298.15%H ₹1,56,454.44 · L ₹1,44,203.56as of 6:06 AM IST|Nifty 5025,800.62.27%H 25,808.8 · L 25,345.2as of 20 Nov, 3:31 PM IST|Sensex83,919.712.3%H 84,037.96 · L 82,403.27as of 20 Nov, 3:32 PM IST|Bank Nifty64,635.24.19%H 64,680.8 · L 62,598.55as of 20 Nov, 3:31 PM IST|USD / INR₹92.660.66%H ₹93.29 · L ₹92.64as of 4:06 AM IST|Gold Intl (10g)₹1,05,429.853.98%H ₹1,08,382.13 · L ₹1,04,363.34as of 3:29 AM IST|Silver Intl (1kg)₹1,22,380.857.39%H ₹1,28,636.93 · L ₹1,20,995.58as of 3:29 AM IST|Crude WTI₹7,748.231.43%H ₹7,789.93 · L ₹7,485.07as of 3:29 AM IST|Bitcoin₹54,62,2015.63%H ₹56,15,877.06 · L ₹53,08,524.94as of 6:06 AM IST|Ethereum₹1,50,3298.15%H ₹1,56,454.44 · L ₹1,44,203.56as of 6:06 AM IST|
0%
real-estate

Aurobindo Pharma Unit Gets USFDA Relief: Apitoria Facility Classified as VAI

Arth Vani DeskPublished: 1 min read
Aurobindo Pharma Unit Gets USFDA Relief: Apitoria Facility Classified as VAI

Source: ET Real Estate

Arth Insight · What this means for your wallet

Immediate action
Investors should monitor the company's upcoming quarterly results to see how stable regulatory clearances translate into export growth.
  • The USFDA has cleared Apitoria Pharma's Andhra facility with a VAI status.
  • A VAI status means minor issues were found but no legal or regulatory action will be taken.
  • This ensures uninterrupted manufacturing and export operations for the subsidiary.
Recommended for you
Check home-loan rates & eligibility
Explore Home Loans
Listen to this article
AI voice · Podcast mode
Get IPO & market alerts free on Telegram / WhatsApp
AI Summary

Aurobindo Pharma's subsidiary, Apitoria Pharma, has received a 'Voluntary Action Indicated' (VAI) status from the US drug regulator for its Andhra Pradesh facility. This classification means that while some issues were found during the August inspection, the USFDA will not pursue any immediate regulatory or administrative action.

Key Highlights
  • ▸The USFDA has cleared Apitoria Pharma's Andhra facility with a VAI status.
  • ▸A VAI status means minor issues were found but no legal or regulatory action will be taken.
  • ▸This ensures uninterrupted manufacturing and export operations for the subsidiary.
  • ▸The inspection took place in late August 2024.
Key Takeaways
  • ✓The USFDA has cleared Apitoria Pharma's Andhra facility with a VAI status.
  • ✓A VAI status means minor issues were found but no legal or regulatory action will be taken.
  • ✓This ensures uninterrupted manufacturing and export operations for the subsidiary.
  • ✓The inspection took place in late August 2024.

Aurobindo Pharma Limited has received a significant regulatory update regarding its subsidiary, Apitoria Pharma Private Limited. The United States Food and Drug Administration (USFDA) has classified the inspection of the subsidiary's manufacturing facility in Andhra Pradesh as "Voluntary Action Indicated" (VAI).

What the VAI Classification Means

A VAI classification is generally viewed as a positive outcome for pharmaceutical companies following a regulatory audit. It indicates that although the USFDA inspectors identified certain objectionable conditions or practices during their visit, these issues do not warrant further regulatory or administrative action at this time. Essentially, the company is expected to correct the observations voluntarily without facing bans or warning letters.

Inspection Timeline and Scope

The regulatory body conducted a thorough inspection of the Apitoria Pharma facility from August 24 to August 28, 2024. The audit focused on compliance with Good Manufacturing Practices (GMP). Following the conclusion of the audit, the USFDA reviewed the facility's responses and internal processes before issuing this final classification.

Impact on Aurobindo Pharma

For investors and stakeholders of Aurobindo Pharma, this news provides a layer of operational certainty. Regulatory hurdles from the USFDA are a primary risk factor for Indian pharma companies exporting to the American market. A VAI status ensures that the facility can continue its production and export activities to the US without the threat of an Import Alert or an Official Action Indicated (OAI) status, which could have halted business.

  • Facility Location: Andhra Pradesh, India
  • Subsidiary: Apitoria Pharma Pvt Ltd
  • Regulator: US Food and Drug Administration (USFDA)
  • Outcome: No regulatory action required

This development is expected to support the stock's sentiment as it clears a major compliance hurdle for one of the company's key manufacturing arms. Investors typically monitor these classifications closely as they directly impact the company's ability to launch new products in the US market.

This report is for informational purposes only and does not constitute financial or investment advice.

Recommended for you
Products related to this story — compare & act
Smart picks
Mirae Asset ELSS Tax Saver Fund
Mirae Asset Mutual Fund · ELSS
13.8%
3Y CAGR
Parag Parikh Flexi Cap Fund
PPFAS Mutual Fund · Flexi Cap
12.8%
3Y CAGR
Nippon India Small Cap Fund
Nippon India Mutual Fund · Small Cap
12.7%
3Y CAGR
Axis ELSS- Tax Saver Fund
Axis Mutual Fund · ELSS
12.7%
3Y CAGR
ICICI Prudential Balanced Advantage Fund
ICICI Prudential Mutual Fund · Hybrid
12.3%
3Y CAGR
HDFC Balanced Advantage Fund
HDFC Mutual Fund · Hybrid
11.8%
3Y CAGR

Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.

Frequently Asked Questions

What does a VAI classification from the USFDA mean?

VAI stands for Voluntary Action Indicated. It means the regulator found some objectionable conditions during an inspection, but they are not serious enough to require administrative or regulatory action. The company is expected to fix these issues voluntarily.

Which Aurobindo Pharma unit was inspected?

The inspection was conducted at the Andhra Pradesh facility of Apitoria Pharma Private Limited, which is a subsidiary of Aurobindo Pharma.

How does this news affect Aurobindo Pharma shareholders?

This is positive news as it reduces regulatory risk. It confirms that the facility meets the necessary standards to continue supplying products to the US market, preventing potential revenue loss from export bans.

Stay ahead of the market

Join the Arth Vani channels

Daily news summaries, IPO & market alerts on Telegram and WhatsApp.

Related Stories

Indian Healthcare Philanthropy Surges 82% to ₹1,768 Crore in FY26
real-estate

Indian Healthcare Philanthropy Surges 82% to ₹1,768 Crore in FY26

Philanthropic contributions to India's healthcare sector surged by 82% to ₹1,768 crore in FY26, according to the EdelGive Hurun India Philanthropy List 2026. This significant growth positions healthcare as the second-most favored cause for donors, with 175 philanthropists participating.

9h ago·2 min readListen
Lord's Mark Industries Reports ₹82 Crore H1 FY27 Profit; Eyes AI Healthcare Expansion by 2027
real-estate

Lord's Mark Industries Reports ₹82 Crore H1 FY27 Profit; Eyes AI Healthcare Expansion by 2027

Lord's Mark Industries Ltd has reported a consolidated net profit of ₹82.01 crore for the first half of the financial year 2026-27 (FY27). The company also announced plans to launch innovative AI-powered healthcare products, including dialysis machines and Sickle Cell screening solutions, by early 2027.

2d ago·2 min readListen
Aragen Life Sciences to Invest ₹1,500 Crore in Expansion Ahead of ₹800 Crore IPO
IPOBreaking
real-estate

Aragen Life Sciences to Invest ₹1,500 Crore in Expansion Ahead of ₹800 Crore IPO

Aragen Life Sciences has announced a ₹1,500 crore capital expenditure plan over the next three years to boost its drug development and manufacturing capacity. The company is preparing for its stock market debut, which includes a fresh issue of shares worth ₹800 crore.

2d ago·1 min readListen
Biocon Secures USFDA Approval for Breast Cancer Biosimilar Pebrilzo
real-estate

Biocon Secures USFDA Approval for Breast Cancer Biosimilar Pebrilzo

Indian biopharmaceutical major Biocon Ltd has received approval from the US Food and Drug Administration (USFDA) for its biosimilar Pebrilzo, a treatment for HER2-positive breast cancer. This milestone expands Biocon's US oncology biosimilar portfolio to five products, with a global launch agreement with Genentech set for 2028.

3d ago·2 min readListen